Recent Patents on Endocrine, Metabolic & Immune Drug ...

Send Orders for Reprints to Recent Patents on endocrine , Metabolic & Immune drug discovery 2015, 9, 000-000 1. abatacept and Glomerular Diseases: The Open Road for the Second Signal as a New Target is Settled Down Hern n Trimarchi*. Nephrology and Kidney Transplant Units, Hospital Brit nico de Buenos Aires, Buenos Aires, Argentina Received: December 8, 2014; Accepted: January 27, 2015; Revised: February 19, 2015. Abstract: Glomerulopathy is the third most important cause of kidney disease. Proteinuria is the hallmark of glomerular damage, and a marker of progression of kidney disease, cardiovascular mor- bidity and mortality. Strategies to reduce proteinuria are partially successful, and despite proteinuria management, renal disease may still progress. Immunosuppression to treat glomerulopathies is non- specific, partially effective and presents side-effects. It is critical to find safe drugs with specific podo- cyte molecular targets. Podocytes contain a complex array of proteins.

Abatacept and Glomerulonephritis Recent Patents on Endocrine, Metabolic & Immune Drug Discovery 2015, Vol. 9, No. 1 3 primary FSGS and in lupus nephritis, and with a small num-

Tags:

  Center, Drug, Endocrine, Immune, Patent, Discovery, Metabolic, Abatacept, Recent patents on endocrine, Metabolic amp immune drug discovery

Information

Related search queries